KRAS and non-small cell lung carcinoma: Our results demonstrate that even after strong EGFR downregulation and concomitant proliferation inhibition, ADCC still provides a mechanism by which imgatuzumab in combination with cetuximab can provide additional antitumor effect, especially in EGFR and KRAS wild-type NSCLC.